Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis

Immunological Reviews

Volumn 246, Issue 1, 2012, Pages 286-310

  Chan, Jonathan K ^a   Greene, Warner C ^a,b  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adult T cell leukemia lymphoma; HIV 1 latency; HTLV 1; NF B

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD40 LIGAND; COLONY STIMULATING FACTOR 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PATTERN RECOGNITION RECEPTOR; PROTEIN BCL XL; PROTEIN P100; PROTEIN P300; PROTEIN P52; RETINOIC ACID INDUCIBLE PROTEIN I; SUPPRESSOR OF CYTOKINE SIGNALING; SURVIVIN; TAX PROTEIN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VIRUS DNA;

ADAPTIVE IMMUNITY; ARTICLE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL IMMORTALIZATION; CELL SURVIVAL; CHROMATIN STRUCTURE; CROSS LINKING; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; DISEASE CARRIER; DNA BINDING; DOWN REGULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; UBIQUITINATION; VIRAL CLEARANCE; VIRUS DNA CELL DNA INTERACTION; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANIMALS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; GENE PRODUCTS, TAX; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNITY, INNATE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; NF-KAPPA B; SIGNAL TRANSDUCTION; VIRAL PROTEINS; VIRUS LATENCY;

EID: 84858714200     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2012.01094.x     Document Type: Article

References (232)

1. Tato CM, Hunter CA. Host-pathogen interactions: subversion and utilization of the NF-kappa B pathway during infection. Infect Immun 2002;70:3311-3317.
2. Yamaoka S, et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 1998;93:1231-1240.
3. Shembade N, Pujari R, Harhaj NS, Abbott DW, Harhaj EW. The kinase IKKalpha inhibits activation of the transcription factor NF-kappaB by phosphorylating the regulatory molecule TAX1BP1. Nat Immunol 2011;12:834-843.
4. Chan JK, Greene WC. NF-kappaB/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS 2011;6:12-18.
5. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987;326:711-713.
6. Brennan K, Bowie AG. Activation of host pattern recognition receptors by viruses. Curr Opin Microbiol 2010;13:503-507.
7. Schroder M, Bowie AG. An arms race: innate antiviral responses and counteracting viral strategies. Biochem Soc Trans 2007;35:1512-1514.
8. van den Elsen PJ, Holling TM, Kuipers HF, van der Stoep N. Transcriptional regulation of antigen presentation. Curr Opin Immunol 2004;16:67-75.
9. Jiao J, Guan H, Lippa AM, Ricciardi RP. The N terminus of adenovirus type 12 E1A inhibits major histocompatibility complex class I expression by preventing phosphorylation of NF-kappaB p65 Ser276 through direct binding. J Virol 2010;84:7668-7674.
10. Piguet V, et al. HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol 2000;2:163-167.
11. Dessain SK, Adekar SP, Berry JD. Exploring the native human antibody repertoire to create antiviral therapeutics. Curr Top Microbiol Immunol 2008;317:155-183.
12. Park SR, et al. HoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutation. Nat Immunol 2009;10:540-550.
13. Gourzi P, Leonova T, Papavasiliou FN. Viral induction of AID is independent of the interferon and the Toll-like receptor signaling pathways but requires NF-kappaB. J Exp Med 2007;204:259-265.
14. Gourzi P, Leonova T, Papavasiliou FN. A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus. Immunity 2006;24:779-786.
15. Rosenberg BR, Papavasiliou FN. Beyond SHM and CSR: AID and related cytidine deaminases in the host response to viral infection. Adv Immunol 2007;94:215-244.
16. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-7419.
17. Sun SC, Cesarman E. NF-kappaB as a target for oncogenic viruses. Curr Top Microbiol Immunol 2011;349:197-244.
18. Banerjee P, Crawford L, Samuelson E, Feuer G. Hematopoietic stem cells and retroviral infection. Retrovirology 2010;7:8.
19. Ceccaldi PE, et al. DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells. J Virol 2006;80:4771-4780.
20. Nagai M, Brennan MB, Sakai JA, Mora CA, Jacobson S. CD8(+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood 2001;98:1858-1861.
21. Kaplan JE, et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990;3:1096-1101.
22. Wattel E, Cavrois M, Gessain A, Wain-Hobson S. Clonal expansion of infected cells: a way of life for HTLV-I. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl):S92-99.
23. Kannagi M, et al. Tumor immunity against adult T-cell leukemia. Cancer Sci 2005;96:249-255.
24. Vahlne A. A historical reflection on the discovery of human retroviruses. Retrovirology 2009;6:40.
25. Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol 2007;37(Suppl):S94-102.
26. Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. Annu Rev Pathol 2011;6:223-248.
27. Greene WC, Depper JM, Kronke M, Leonard WJ. The human interleukin-2 receptor: analysis of structure and function. Immunol Rev 1986;92:29-48.
28. Shimizu A, Kondo S, Sabe H, Ishida N, Honjo T. Structure and function of the interleukin 2 receptor: affinity conversion model. Immunol Rev 1986;92:103-120.
29. Taniguchi T, et al. Molecular analysis of the interleukin-2 system. Immunol Rev 1986;92:121-133.
30. Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Greene WC. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature 1982;300:267-269.
31. Leonard WJ, et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 1984;311:626-631.
32. Leonard WJ, et al. Structure of the human interleukin-2 receptor gene. Science 1985;230:633-639.
33. Leonard WJ, Donlon TA, Lebo RV, Greene WC. Localization of the gene encoding the human interleukin-2 receptor on chromosome 10. Science 1985;228:1547-1549.
34. Waldmann TA, et al. Interleukin-2 receptor expression in retrovirus associated adult T-cell leukemia. Princess Takamatsu Symp 1984;15:259-268.
35. Depper JM, Leonard WJ, Kronke M, Waldmann TA, Greene WC. Augmented T cell growth factor receptor expression in HTLV-1-infected human leukemic T cells. J Immunol 1984;133:1691-1695.
36. Greene WC, Bohnlein E, Ballard DW. HIV-1, HTLV-1 and normal T-cell growth: transcriptional strategies and surprises. Immunol Today 1989;10:272-278.
37. Wano Y, Feinberg M, Hosking JB, Bogerd H, Greene WC. Stable expression of the tax gene of type I human T-cell leukemia virus in human T cells activates specific cellular genes involved in growth. Proc Natl Acad Sci USA 1988;85:9733-9737.
38. McKnight S, Tjian R. Transcriptional selectivity of viral genes in mammalian cells. Cell 1986;46:795-805.
39. Ballard DW, Bohnlein E, Lowenthal JW, Wano Y, Franza BR, Greene WC. HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science 1988;241:1652-1655.
40. Hoyos B, Ballard DW, Bohnlein E, Siekevitz M, Greene WC. Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science 1989;244:457-460.
41. Kronke M, Leonard WJ, Depper JM, Greene WC. Deregulation of interleukin-2 receptor gene expression in HTLV-I-induced adult T-cell leukemia. Science 1985;228:1215-1217.
42. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006;6:595-601.
43. Siekevitz M, Feinberg MB, Holbrook N, Wong-Staal F, Greene WC. Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I. Proc Natl Acad Sci USA 1987;84:5389-5393.
44. Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC. Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Science 1987;238:1575-1578.
45. Kronke M, Depper JM, Leonard WJ, Vitetta ES, Waldmann TA, Greene WC. Adult T cell leukemia: a potential target for ricin A chain immunotoxins. Blood 1985;65:1416-1421.
46. Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 2003;63:6453-6457.
47. Zhang Z, et al. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood 2006;108:1007-1012.
48. Bohnlein E, Lowenthal JW, Siekevitz M, Ballard DW, Franza BR, Greene WC. The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Cell 1988;53:827-836.
49. Molitor JA, Walker WH, Doerre S, Ballard DW, Greene WC. NF-kappa B: a family of inducible and differentially expressed enhancer-binding proteins in human T cells. Proc Natl Acad Sci USA 1990;87:10028-10032.
50. Arima N, Molitor JA, Smith MR, Kim JH, Daitoku Y, Greene WC. Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kappa B enhancer-binding proteins: evidence for a pretranslational component of regulation. J Virol 1991;65:6892-6899.
51. Ghosh S, Gifford AM, Riviere LR, Tempst P, Nolan GP, Baltimore D. Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Cell 1990;62:1019-1029.
52. Kieran M, et al. The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. Cell 1990;62:1007-1018.
53. Nolan GP, Ghosh S, Liou HC, Tempst P, Baltimore D. DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell 1991;64:961-969.
54. Ruben SM, et al. Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. Science 1991;251:1490-1493.
55. Lee JH, et al. A member of the set of kappa B binding proteins, HIVEN86A, is a product of the human c-rel proto-oncogene. Oncogene 1991;6:665-667.
56. Doerre S, Sista P, Sun SC, Ballard DW, Greene WC. The c-rel protooncogene product represses NF-kappa B p65-mediated transcriptional activation of the long terminal repeat of type 1 human immunodeficiency virus. Proc Natl Acad Sci USA 1993;90:1023-1027.
57. Smith MR, Greene WC. Identification of HTLV-I tax trans-activator mutants exhibiting novel transcriptional phenotypes. Genes Dev 1990;4:1875-1885.
58. Stephens RM, Rice NR, Hiebsch RR, Bose HR Jr, Gilden RV. Nucleotide sequence of v-rel: the oncogene of reticuloendotheliosis virus. Proc Natl Acad Sci USA 1983;80:6229-6233.
59. Wilhelmsen KC, Temin HM. Structure and dimorphism of c-rel (turkey), the cellular homolog to the oncogene of reticuloendotheliosis virus strain T. J Virol 1984;49:521-529.
60. Ballard DW, et al. The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell 1990;63:803-814.
61. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 1999;18:6925-6937.
62. Haskill S, et al. Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell 1991;65:1281-1289.
63. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 1993;259:1912-1915.
64. Sun SC, Elwood J, Beraud C, Greene WC. Human T-cell leukemia virus type I Tax activation of NF-kappa B/Rel involves phosphorylation and degradation of I kappa B alpha and RelA (p65)-mediated induction of the c-rel gene. Mol Cell Biol 1994;14:7377-7384.
65. Geleziunas R, et al. Human T-cell leukemia virus type 1 Tex induction of NF-κB involves activation of the IκB kinase alpha (IKKalpha) and IKKbeta cellular kineses. Mol Cell Biol 1998;18:5157-5165.
66. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001;293:1653-1657.
67. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 2002;21:6539-6548.
68. Yeung F, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004;23:2369-2380.
69. Kwon HS, et al. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 2008;3:158-167.
70. Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol 2009;29:1375-1387.
71. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006;25:139-149.
72. Williams SA, Kwon H, Chen LF, Greene WC. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol 2007;81:6043-6056.
73. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009;323:1304-1307.
74. Kim YM, Geiger TR, Egan DI, Sharma N, Nyborg JK. The HTLV-1 tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription. Oncogene 2010;29:2142-2152.
75. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007;7:270-280.
76. Marriott SJ, Semmes OJ. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005;24:5986-5995.
77. Ching YP, Chan SF, Jeang KT, Jin DY. The retroviral oncoprotein Tax targets the coiled-coil centrosomal protein TAX1BP2 to induce centrosome overduplication. Nat Cell Biol 2006;8:717-724.
78. Igakura T, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003;299:1713-1716.
79. Barnard AL, Igakura T, Tanaka Y, Taylor GP, Bangham CR. Engagement of specific T-cell surface molecules regulates cytoskeletal polarization in HTLV-1-infected lymphocytes. Blood 2005;106:988-995.
80. Tanaka Y, Hayashi M, Takagi S, Yoshie O. Differential transactivation of the intercellular adhesion molecule 1 gene promoter by Tax1 and Tax2 of human T-cell leukemia viruses. J Virol 1996;70:8508-8517.
81. Oliere S, et al. HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog 2010;6:e1001177.
82. Akhtar LN, Benveniste EN. Viral exploitation of host SOCS protein functions. J Virol 2011;85:1912-1921.
83. Charoenthongtrakul S, Zhou Q, Shembade N, Harhaj NS, Harhaj EW. Human T cell leukemia virus type 1 Tax inhibits innate antiviral signaling via NF-kappaB-dependent induction of SOCS1. J Virol 2011;85:6955-6962.
84. Alefantis T, Mostoller K, Jain P, Harhaj E, Grant C, Wigdahl B. Secretion of the human T cell leukemia virus type I transactivator protein tax. J Biol Chem 2005;280:17353-17362.
85. Kinpara S, et al. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J Virol 2009;83:5101-5108.
86. Kawakami H, et al. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer 2005;115:967-974.
87. Bernal-Mizrachi L, Lovly CM, Ratner L. The role of NF-κB-1 and NF-κB-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci USA 2006;103:9220-9225.
88. Iwanaga R, et al. Activation of the cyclin D2 and cdk6 genes through NF-kappaB is critical for cell-cycle progression induced by HTLV-I Tax. Oncogene 2008;27:5635-5642.
89. Lanoix J, Lacoste J, Pepin N, Rice N, Hiscott J. Overproduction of NFKB2 (lyt-10) and c-Rel: a mechanism for HTLV-I Tax-mediated trans-activation via the NF-kappa B signalling pathway. Oncogene 1994;9:841-852.
90. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-6947.
91. Isogawa M, et al. Rearranged NF-kappa B2 gene in an adult T-cell leukemia cell line. Cancer Sci 2008;99:792-798.
92. Higuchi M, et al. Cooperation of NF-kappaB2/p100 activation and the PDZ domain binding motif signal in human T-cell leukemia virus type 1 (HTLV-1) Tax1 but not HTLV-2 Tax2 is crucial for interleukin-2-independent growth transformation of a T-cell line. J Virol 2007;81:11900-11907.
93. Kress AK, Kalmer M, Rowan AG, Grassmann R, Fleckenstein B. The tumor marker Fascin is strongly induced by the Tax oncoprotein of HTLV-1 through NF-kappaB signals. Blood 2011;117:3609-3612.
94. Robek MD, Ratner L. Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone. J Virol 1999;73:4856-4865.
95. Gao L, et al. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 2005;106:4294-4302.
96. Kwon H, et al. Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. J Biol Chem 2005;280:35713-35722.
97. Hasegawa H, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med 2006;12:466-472.
98. Ohsugi T, Kumasaka T, Okada S, Urano T. The Tax protein of HTLV-1 promotes oncogenesis in not only immature T cells but also mature T cells. Nat Med 2007;13:527-528.
99. Kanarek N, Ben-Neriah Y. Regulation of NFkB by ubiquitination and degradation of the IkBs. Immunol Rev 2012;246:77-94.
100. Chen ZJ. Ubiquitination in signaling to and activation of IKK. Immunol Rev 2012;246:95-106.
101. Liu F, Xia Y, Parker AS, Verma IM. IKK biology. Immunol Rev 2012;246:239-253.
102. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem 2009;78:769-796.
103. Sun SC. Deubiquitylation and regulation of the immune response. Nat Rev Immunol 2008;8:501-511.
104. Harhaj EW, Dixit VM. Regulation of NF-kB by deubiquitinases. Immunol Rev 2012;246:107-124.
105. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010;327:1135-1139.
106. Nicot C, Tie F, Giam CZ. Cytoplasmic forms of human T-cell leukemia virus type 1 Tax induce NF-kappaB activation. J Virol 1998;72:6777-6784.
107. Alefantis T, Barmak K, Harhaj EW, Grant C, Wigdahl B. Characterization of a nuclear export signal within the human T cell leukemia virus type I transactivator protein Tax. J Biol Chem 2003;278:21814-21822.
108. Shembade N, Harhaj NS, Yamamoto M, Akira S, Harhaj EW. The human T-cell leukemia virus type 1 Tax oncoprotein requires the ubiquitin-conjugating enzyme Ubc13 for NF-kappaB activation. J Virol 2007;81:13735-13742.
109. Wu X, Sun SC. Retroviral oncoprotein Tax deregulates NF-kappaB by activating Tak1 and mediating the physical association of Tak1-IKK. EMBO Rep 2007;8:510-515.
110. Harhaj NS, Sun SC, Harhaj EW. Activation of NF-kappa B by the human T cell leukemia virus type I Tax oncoprotein is associated with ubiquitin-dependent relocalization of I kappa B kinase. J Biol Chem 2007;282:4185-4192.
111. Kfoury Y, et al. Ubiquitylated Tax targets and binds the IKK signalosome at the centrosome. Oncogene 2008;27:1665-1676.
112. Nasr R, et al. Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-kappaB activation. Blood 2006;107:4021-4029.
113. Huang J, Ren T, Guan H, Jiang Y, Cheng H. HTLV-1 Tax is a critical lipid raft modulator that hijacks IkappaB kinases to the microdomains for persistent activation of NF-kappaB. J Biol Chem 2009;284:6208-6217.
114. Xiao G, Harhaj EW, Sun SC. Domain-specific interaction with the I kappa B kinase (IKK) regulatory subunit IKK gamma is an essential step in tax-mediated activation of IKK. J Biol Chem 2000;275:34060-34067.
115. Journo C, et al. NRP/Optineurin Cooperates with TAX1BP1 to potentiate the activation of NF-kappaB by human T-lymphotropic virus type 1 tax protein. PLoS Pathog 2009;5:e1000521.
116. Peloponese JM Jr, Yasunaga J, Kinjo T, Watashi K, Jeang KT. Peptidylproline cis-trans-isomerase Pin1 interacts with human T-cell leukemia virus type 1 tax and modulates its activation of NF-kappaB. J Virol 2009;83:3238-3248.
117. Ryo A, et al. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003;12:1413-1426.
118. Chen LF, et al. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 2005;25:7966-7975.
119. Fu J, et al. The tumor suppressor gene WWOX links the canonical and noncanonical NF-kappaB pathways in HTLV-I Tax-mediated tumorigenesis. Blood 2011;117:1652-1661.
120. O'Mahony AM, Montano M, Van Beneden K, Chen LF, Greene WC. Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65. J Biol Chem 2004;279:18137-18145.
121. Lodewick J, et al. Acetylation of the human T-cell leukemia virus type 1 Tax oncoprotein by p300 promotes activation of the NF-kappaB pathway. Virology 2009;386:68-78.
122. Hutti JE, Turk BE, Asara JM, Ma A, Cantley LC, Abbott DW. IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol 2007;27:7451-7461.
123. Dobrzanski P, Ryseck RP, Bravo R. Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100. Oncogene 1995;10:1003-1007.
124. Qing G, Qu Z, Xiao G. Regulation of NF-kappa B2 p100 processing by its cis-acting domain. J Biol Chem 2005;280:18-27.
125. Sun S-C. The noncanonical NF-kB pathway. Immunol Rev 2012;246:125-140.
126. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004;279:26243-26250.
127. Qing G, Qu Z, Xiao G. Stabilization of basally translated NF-kappaB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-kappaB2 p100. J Biol Chem 2005;280:40578-40582.
128. Vallabhapurapu S, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008;9:1364-1370.
129. Liang C, Zhang M, Sun SC. beta-TrCP binding and processing of NF-kappaB2/p100 involve its phosphorylation at serines 866 and 870. Cell Signal 2006;18:1309-1317.
130. Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem 2004;279:30099-30105.
131. Fong A, Sun SC. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100. J Biol Chem 2002;277:22111-22114.
132. Qing G, Qu Z, Xiao G. Endoproteolytic processing of C-terminally truncated NF-kappaB2 precursors at kappaB-containing promoters. Proc Natl Acad Sci USA 2007;104:5324-5329.
133. Liao G, Sun SC. Regulation of NF-kappaB2/p100 processing by its nuclear shuttling. Oncogene 2003;22:4868-4874.
134. Beraud C, Sun SC, Ganchi P, Ballard DW, Greene WC. Human T-cell leukemia virus type I Tax associates with and is negatively regulated by the NF-kappa B2 p100 gene product: implications for viral latency. Mol Cell Biol 1994;14:1374-1382.
135. Xiao G, et al. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J 2001;20:6805-6815.
136. Dobrzanski P, Ryseck RP, Bravo R. Both N- and C-terminal domains of RelB are required for full transactivation: role of the N-terminal leucine zipper-like motif. Mol Cell Biol 1993;13:1572-1582.
137. Shoji T, et al. Identification of a novel motif responsible for the distinctive transforming activity of human T-cell leukemia virus (HTLV) type 1 Tax1 protein from HTLV-2 Tax2. Retrovirology 2009;6:83.
138. Zhi H, Yang L, Kuo YL, Ho YK, Shih HM, Giam CZ. NF-kappaB hyper-activation by HTLV-1 tax induces cellular senescence, but can be alleviated by the viral anti-sense protein HBZ. PLoS Pathog 2011;7:e1002025.
139. Kim YM, Sharma N, Nyborg JK. The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter. J Virol 2008;82:11939-11947.
140. Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA 2006;103:720-725.
141. Yan P, et al. PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation. Blood 2009;113:4370-4380.
142. Zhao T, et al. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood 2009;113:2755-2764.
143. Arnold J, Zimmerman B, Li M, Lairmore MD, Green PL. Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation. Blood 2008;112:3788-3797.
144. Hironaka N, Mochida K, Mori N, Maeda M, Yamamoto N, Yamaoka S. Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. Neoplasia 2004;6:266-278.
145. Ramos JC, et al. IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood 2007;109:3060-3068.
146. Saitoh Y, et al. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood 2008;111:5118-5129.
147. O'Mahony A, Lin X, Geleziunas R, Greene WC. Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol Cell Biol 2000;20:1170-1178.
148. Zarnegar B, Yamazaki S, He JQ, Cheng G. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci USA 2008;105:3503-3508.
149. Nitta T, et al. Reduction of human T-cell leukemia virus type-1 infection in mice lacking nuclear factor-kappaB-inducing kinase. Cancer Sci 2008;99:872-878.
150. Brass AL, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008;319:921-926.
151. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J 1993;12:3551-3558.
152. West MJ, Lowe AD, Karn J. Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J Virol 2001;75:8524-8537.
153. Zhou H, et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008;4:495-504.
154. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010;84:5958-5974.
155. Alcami J, et al. Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J 1995;14:1552-1560.
156. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 2001;8:327-337.
157. Hottiger MO, Felzien LK, Nabel GJ. Modulation of cytokine-induced HIV gene expression by competitive binding of transcription factors to the coactivator p300. EMBO J 1998;17:3124-3134.
158. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008;8:447-457.
159. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990;9:1551-1560.
160. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-222.
161. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M Jr. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 2009;83:10395-10405.
162. Doitsh G, et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010;143:789-801.
163. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004;427:848-853.
164. Pertel T, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011;472:361-365.
165. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010;464:217-223.
166. Cavrois M, Neidleman J, Kreisberg JF, Greene WC. In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions. PLoS Pathog 2007;3:e4.
167. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TB. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 2011;11:419-426.
168. Mehandru S, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200:761-770.
169. Mehandru S, et al. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol 2007;81:599-612.
170. Sankaran S, et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol 2008;82:538-545.
171. Peut V, Kent SJ. Fitness constraints on immune escape from HIV: Implications of envelope as a target for both HIV-specific T cells and antibody. Curr HIV Res 2006;4:191-197.
172. Nowak DE, et al. RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. Mol Cell Biol 2008;28:3623-3638.
173. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TB. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 2010;11:419-426.
174. Ott M, et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997;275:1481-1485.
175. Xu W, et al. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 2009;10:1008-1017.
176. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006;7:302-310.
177. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998;95:8869-8873.
178. Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 2007;5:95-106.
179. Zhang L, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000;106:839-845.
180. Chun TW, et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000;6:757-761.
181. Chomont N, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15:893-900.
182. Riou C, et al. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J Exp Med 2007;204:79-91.
183. Fritsch RD, Shen X, Sims GP, Hathcock KS, Hodes RJ, Lipsky PE. Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol 2005;175:6489-6497.
184. Gerondakis S, et al. NF-kB subunit specificity in hemopoiesis. Immunol Rev 2012;246:272-285.
185. Song J, So T, Croft M. Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol 2008;180:7240-7248.
186. Duverger A, et al. Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol 2009;83:3078-3093.
187. Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 2007;8:584-591.
188. Yang XD, Huang B, Li M, Lamb A, Kelleher NL, Chen LF. Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. EMBO J 2009;28:1055-1066.
189. Levy D, et al. Lysine methylation of the NF-kappaB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-kappaB signaling. Nat Immunol 2011;12:29-36.
190. Stroud JC, Oltman A, Han A, Bates DL, Chen L. Structural basis of HIV-1 activation by NF-kappaB-a higher-order complex of p50:RelA bound to the HIV-1 LTR. J Mol Biol 2009;393:98-112.
191. Burnett JC, Miller-Jensen K, Shah PS, Arkin AP, Schaffer DV. Control of stochastic gene expression by host factors at the HIV promoter. PLoS Pathog 2009;5:e1000260.
192. Chetoui N, Boisvert M, Gendron S, Aoudjit F. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology 2010;130:418-426.
193. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009;5:e1000495.
194. Reuse S, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 2009;4:e6093.
195. Han Y, et al. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 2008;4:134-146.
196. Lenasi T, Contreras X, Peterlin BM. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 2008;4:123-133.
197. Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010;84:6425-6437.
198. Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2006;2:e68.
199. Huang J, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007;13:1241-1247.
200. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003;22:1868-1877.
201. Blazkova J, et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009;5:e1000554.
202. Marsden MD, Burke BP, Zack JA. HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes. Virology 2011;417:394-399.
203. Imai K, Togami H, Okamoto T. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem 2011;285:16538-16545.
204. Shinkai Y, Tachibana M. H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev 2011;25:781-788.
205. Williams SA, et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 2004;279:42008-42017.
206. Swiggard WJ, et al. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol 2005;79:14179-14188.
207. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2009;113:58-65.
208. Yang HC, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009;119:3473-3486.
209. Frischbutter S, Gabriel C, Bendfeldt H, Radbruch A, Baumgrass R. Dephosphorylation of Bcl-10 by calcineurin is essential for canonical NF-kappaB activation in Th cells. Eur J Immunol 2011;41:2349-2357.
210. 2+ influx. Functional synergy between Raf and calcineurin. J Immunol 1996;157:5277-5283.
211. 2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation. J Biol Chem 2011;286:7522-7534.
212. Trushin SA, Pennington KN, Algeciras-Schimnich A, Paya CV. Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. J Biol Chem 1999;274:22923-22931.
213. Trushin SA, et al. Protein kinase Calpha (PKCalpha) acts upstream of PKCtheta to activate IkappaB kinase and NF-kappaB in T lymphocytes. Mol Cell Biol 2003;23:7068-7081.
214. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004;14:289-301.
215. Jiang C, Lin X. Regulation of NF-kB by the CARD proteins. Immnol Rev 2012;246:311-326.
216. 2+ signaling. Genes Dev 2008;22:1356-1368.
217. Kim YK, Mbonye U, Hokello J, Karn J. T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. J Mol Biol 2011;410:896-916.
218. Marquez N, et al. Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation. Biochem Pharmacol 2008;75:1370-1380.
219. Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood 2011;118:1736-1745.
220. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010;1799:775-787.
221. Prins JM, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999;13:2405-2410.
222. Stellbrink HJ, et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002;16:1479-1487.
223. Archin NM, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS ONE 2010;5:e9390.
224. Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem 2011;286:22211-22218.
225. Vedadi M, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 2011;7:566-574.
226. Perez M, et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res 2010;8:418-429.
227. Ariza ME, Ramakrishnan R, Singh NP, Chauhan A, Nagarkatti PS, Nagarkatti M. Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells. J Biol Chem 2011;286:24-34.
228. Xing S, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011;85:6060-6064.
229. Harhaj EW, Sun SC. IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein. J Biol Chem 1999;274:22911-22914.
230. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000;18:621-663.
231. Qu Z, Qing G, Rabson A, Xiao G. Tax deregulation of NF-kappaB2 p100 processing involves both beta-TrCP-dependent and -independent mechanisms. J Biol Chem 2004;279:44563-44572.
232. Qing G, Xiao G. Essential role of IkappaB kinase alpha in the constitutive processing of NF-kappaB2 p100. J Biol Chem 2005;280:9765-9768.